{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T10:48:12Z","timestamp":1740134892551,"version":"3.37.3"},"reference-count":10,"publisher":"American Society of Hematology","issue":"23","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,6,6]]},"DOI":"10.1182\/blood.2024024414","type":"journal-article","created":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T15:32:17Z","timestamp":1717687937000},"page":"2344-2345","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":0,"title":["Blood, the hidden side of myeloma?"],"prefix":"10.1182","volume":"143","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1580-6106","authenticated-orcid":false,"given":"Jill","family":"Corre","sequence":"first","affiliation":[{"name":"Institut Universitaire du Cancer de Toulouse Oncopole"},{"name":"Centre de Recherches en Canc\u00e9rologie de Toulouse"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"23","key":"2024060615320474700_bib1","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1182\/blood.2023022540","article-title":"ctDNA improves prognostic prediction for patients with relapsed\/refractory MM receiving ixazomib, lenalidomide, and dexamethasone","volume":"143","author":"Kogure","year":"2024","journal-title":"Blood"},{"issue":"2","key":"2024060615320474700_bib2","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3390\/cells9020287","article-title":"Prognosis, biology, and targeting of TP53 dysregulation in multiple myeloma","volume":"9","author":"Flynt","year":"2020","journal-title":"Cells"},{"issue":"9","key":"2024060615320474700_bib3","doi-asserted-by":"crossref","first-page":"e480","DOI":"10.3324\/haematol.2019.236588","article-title":"Early relapse after autologous transplant for myeloma is associated with poor survival regardless of cytogenetic risk","volume":"105","author":"Corre","year":"2020","journal-title":"Haematologica"},{"issue":"3","key":"2024060615320474700_bib4","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/bjh.15782","article-title":"The impact of cytogenetics on duration of response and overall survival in patients with relapsed multiple myeloma (long-term follow-up results from BSBMT\/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial","volume":"185","author":"Cook","year":"2019","journal-title":"Br J Haematol"},{"issue":"1","key":"2024060615320474700_bib5","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/s41467-017-00296-y","article-title":"Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing","volume":"8","author":"Rasche","year":"2017","journal-title":"Nat Commun"},{"key":"2024060615320474700_bib6","doi-asserted-by":"crossref","first-page":"15086","DOI":"10.1038\/ncomms15086","article-title":"Circulating\u00a0tumour DNA sequence analysis as an alternative to multiple myeloma bone marrow aspirates","volume":"8","author":"Kis","year":"2017","journal-title":"Nat Commun"},{"issue":"1","key":"2024060615320474700_bib7","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1038\/s41467-018-04001-5","article-title":"Whole-exome sequencing of cell-free DNA\u00a0and circulating tumor cells in multiple\u00a0myeloma","volume":"9","author":"Manier","year":"2018","journal-title":"Nat Commun"},{"issue":"33","key":"2024060615320474700_bib8","doi-asserted-by":"crossref","first-page":"3911","DOI":"10.1200\/JCO.2014.59.1503","article-title":"Mutational spectrum, copy number changes, and outcome: results of a sequencing study of patients with newly diagnosed myeloma","volume":"33","author":"Walker","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"2024060615320474700_bib9","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1200\/JCO.21.01987","article-title":"In multiple myeloma, high-risk secondary genetic events observed at relapse are present from diagnosis in tiny, undetectable subclonal populations","volume":"41","author":"Lannes","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"2024060615320474700_bib10","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41467-020-20524-2","article-title":"The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma","volume":"12","author":"Boyle","year":"2021","journal-title":"Nat Commun"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/143\/23\/2344\/2228002\/blood_bld-2024-024414-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/143\/23\/2344\/2228002\/blood_bld-2024-024414-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T15:32:23Z","timestamp":1717687943000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/143\/23\/2344\/516254\/Blood-the-hidden-side-of-myeloma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,6]]},"references-count":10,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2024,6,6]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2024024414","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"type":"print","value":"0006-4971"},{"type":"electronic","value":"1528-0020"}],"subject":[],"published":{"date-parts":[[2024,6,6]]}}}